Odontoprev SA
BOVESPA:ODPV3

Watchlist Manager
Odontoprev SA Logo
Odontoprev SA
BOVESPA:ODPV3
Watchlist
Price: 15.25 BRL 3.53%
Market Cap: R$8.4B

EV/GP

9.2
Current
29%
More Expensive
vs 3-y average of 7.1

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
9.2
=
Enterprise Value
R$7.1B
/
Gross Profit
R$870.3m

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
9.2
=
Enterprise Value
R$7.1B
/
Gross Profit
R$870.3m

Valuation Scenarios

Odontoprev SA is trading above its 3-year average

If EV/GP returns to its 3-Year Average (7.1), the stock would be worth R$11.8 (23% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-67%
Maximum Upside
No Upside Scenarios
Average Downside
42%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 9.2 R$15.25
0%
3-Year Average 7.1 R$11.8
-23%
5-Year Average 6.4 R$10.5
-31%
Industry Average 3 R$4.99
-67%
Country Average 4.9 R$8.1
-47%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
BR
Odontoprev SA
BOVESPA:ODPV3
8.3B BRL 9.2 14.3
US
UnitedHealth Group Inc
NYSE:UNH
336.3B USD 0 27.9
US
Anthem Inc
LSE:0HG8
96.4B USD 0 18.3
US
Elevance Health Inc
NYSE:ELV
81.8B USD 0 15.5
US
Humana Inc
NYSE:HUM
28.5B USD 0 24
US
Centene Corp
NYSE:CNC
26.4B USD 0 -3.9
US
Molina Healthcare Inc
NYSE:MOH
10.1B USD 0.8 53.4
US
Healthequity Inc
NASDAQ:HQY
7B USD 8.2 32.4
US
Magellan Health Inc
F:MAH1
2.2B EUR 13.3 8.5
US
Progyny Inc
NASDAQ:PGNY
1.5B USD 3.8 26.4
US
Clover Health Investments Corp
NASDAQ:CLOV
1.4B USD 0 -16
P/E Multiple
Earnings Growth PEG
BR
Odontoprev SA
BOVESPA:ODPV3
Average P/E: 24.5
14.3
4%
3.6
US
UnitedHealth Group Inc
NYSE:UNH
27.9
22%
1.3
US
A
Anthem Inc
LSE:0HG8
18.3
10%
1.8
US
Elevance Health Inc
NYSE:ELV
15.5
10%
1.6
US
Humana Inc
NYSE:HUM
24
38%
0.6
US
Centene Corp
NYSE:CNC
Negative Multiple: -3.9 N/A N/A
US
Molina Healthcare Inc
NYSE:MOH
53.4
14%
3.8
US
Healthequity Inc
NASDAQ:HQY
32.4
32%
1
US
M
Magellan Health Inc
F:MAH1
8.5
N/A N/A
US
Progyny Inc
NASDAQ:PGNY
26.4
35%
0.8
US
Clover Health Investments Corp
NASDAQ:CLOV
Negative Multiple: -16 N/A N/A

Market Distribution

Higher than 81% of companies in Brazil
Percentile
81th
Based on 434 companies
81th percentile
9.2
Low
0.3 — 3.1
Typical Range
3.1 — 6.9
High
6.9 —
Distribution Statistics
Brazil
Min 0.3
30th Percentile 3.1
Median 4.9
70th Percentile 6.9
Max 121

Odontoprev SA
Glance View

Market Cap
8.4B BRL
Industry
Health Care

OdontoPrev SA engages in the provision of dental and oral health solutions. The company is headquartered in Barueri, Sao Paulo. The company went IPO on 2006-12-01. The firm is involved in the management, sale and provision of private dental care plans and services. The company offers services to individual and corporate customers. The firm organizes its dental care services into three main segments: Collective Pre-paid Plans, Collective Post-paid Plans and Individual Pre-paid Plans. Through its indirect subsidiary Easy Software Ltda, the Company is also active in the development of computer software for the dental industry. Odontoprev SA holds shares in various direct subsidiaries, such as Clidec - Clinica Dentaria Especializada Cura Dar's Ltda, Odontoprev Servicos Ltda, Garcia Pedrosa Ltda and Adcon Administradora de Convenios Odontologicos Ltd. Furthermore, It is a subsidiary of Bradesco Saude SA, a unit of Banco Bradesco SA's Bradesco Seguros e Previdencia SA.

ODPV3 Intrinsic Value
9.6 BRL
Overvaluation 37%
Intrinsic Value
Price R$15.25
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett